Cramer’s Investing Club: We are making our first new buy of 2022
(This article was sent first to members of the CNBC Investing Club with Jim Cramer. To get the real-time updates in your inbox, subscribe here.)
After you receive this email, we will be initiating a position in Danaher (DHR), buying 100 shares at roughly $312.60. Following the trade, the Charitable trust will own 100 shares of Danaher. The position will represent approximately 0.75% of the portfolio.
The healthcare sector is kicking off the year’s first trading day on the decline and is one of the worst-performing sectors despite the positive start for the broader market. Today’s weakness follows a period of strength, as healthcare was in favor throughout a volatile December thanks to the group’s defensive qualities. When investors get concerned about an economic slowdown or supply chain uncertainties, they often turn to healthcare because the sector doesn’t need a fast-growing economy to expand earnings and deliver on its targets.
We did some profit-taking in a couple of healthcare names last week, trimming AbbVie (ABBV) (as it made a new 52-week high day after day) and some shares of Abbott Laboratories (ABT) into its recent run. But with healthcare on the decline today and our positive view on the sector still intact, we see today’s weakness as an opportunity to redeploy the cash we raised from our other healthcare names and buy shares in one of the highest-quality names in the entire group: Danaher.
Breaking down Danaher’s businesses
Danaher operates through three main segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. While Danaher may be considered a multi-industry name, some of the common themes across Danaher’s entire portfolio are a focus on high value and mission-critical applications, consumable revenue streams off an extensive installed base (75% of Danaher’s portfolio is recurring), and exposure to long-term secular growth trends.
By segment, Life Sciences is the largest and makes up about 52% of the company’s estimated total 2021 revenue. Danaher’s Life Sciences platform had a very strong 2021, with core revenue growth expected to exceed 20% with operating margins above 25%. The global growth drivers behind the strong trends within Life Sciences are the shift towards biologics, increased focus on genomic medicine, and vaccine, therapeutics, and research in response to COVID-19.
Danaher’s Life Science business was boosted over the past few years through several acquisitions, most notably Cytiva (which was purchased at a great price from General Electric) and the recently closed Aldevron deal. Cytiva gave Danaher leadership in the fast growing bioprocessing market, and Aldevron is a leading producer of high quality plasmid DNA, mRNA, and proteins with exposure to the fast growing genomic medicine industry.
Next is Diagnostics, which is expected to make up about 32% of Danaher’s 2021 revenues. Danaher’s portfolio has a strong position across the entire diagnostics landscape, whether it be in molecular through Cepheid, “niche” areas from Leica and Radiometer, or a lab presence with Beckman Coulter. Cepheid is the business we want to focus on. It may be best known for its COVID-19 tests (and they will ship 55 million tests in 2021 alone), but the longer-term story here is how COVID-19 has accelerated the decentralization of healthcare to settings closer to the patient at the point of care because it is faster and more accessible. This has created a growth catalyst for the molecular diagnostic industry at large, but Cepheid is best positioned to be the winner because it has the largest installed base and most extensive menu in all of molecular diagnostics.
Lastly is Environmental & Applied Solutions, which is expected to make up about 16% of Danaher’s 2021 revenues. This segment is split between a portfolio that focuses on Water Quality and another that specializes in Product Identification. Both are quality assets that are growing faster than industry peers.
Why we like Danaher
In addition to exposure to secular growing end markets, what makes Danaher such a quality name is management’s track record of execution. Management is constantly delivering operational improvements through the application of the Danaher Business System. This playbook is Danaher’s competitive advantage, and it has become a powerful source of business improvement. Across the portfolio, Danaher is focused on improving the cost structure, reinvesting for growth, and accelerating margins & core growth of its different businesses. It’s continuous improvement, but where it happens best is with M&A, which is Danaher’s bread and butter. Danaher is so good at buying businesses and then accelerating growth while also improving margins. If you take a look at the slide deck from Danaher’s 2018 DBS overview at the link here, you will see the DBS in action.
Danaher’s durable, recurring revenue streams, exposure to secular growing end markets, M&A execution and constant operational improvements have created an attractive long-term growth model. At Danaher’s September Analyst Day, management provided long-term guidance of mid-single-digit core revenue growth (accelerating from 5-6% pre-2019), 50 to 75 basis point operating margin expansion, strong free cash flow with conversion (FCF divided by net income) greater than 100% plus more acquisitions. Putting it all together, Danaher believes it will achieve double-digit earnings per share growth over the long term. Danaher’s continuous operational improvements of a portfolio based on recurring revenue streams have made this company quite the earnings compounder.
We are initiating Danaher with aprice target of $360, representing roughly 35x the FactSet consensus estimate for 2022 earnings per share. The stock isn’t cheap, but Danaher consistently trades at a premium because of its high-quality business model, management’s M&A track record, and long history of continuous operational improvements through the Danaher Business System. Also, we think this premium will be justified should core revenue growth accelerate from its pre-2019 level as management expects. And current 2022 revenue estimate may be conservative because COVID-19 tailwinds (from testing and vaccine & therapeutics) are proving to be more durable than previously thought.
As always, we never like to buy all at once when we put on a new stock position for the Charitable Trust. We prefer to scale deeper over time, explaining why we are starting relatively small this morning with a starter position. But with shares pulling back about 5% today and nicely down from their ~$333 high, we believe this dip has created an attractive entry point.
The CNBC Investing Club is now the official home to my Charitable Trust. It’s the place where you can see every move we make for the portfolio and get my market insight before anyone else. The Charitable Trust and my writings are no longer affiliated with Action Alerts Plus in any way.
As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. See here for the investing disclaimer.
(Jim Cramer’s Charitable Trust is long DHR, ABBV, ABT.)